| Cancer of the Larynx |
|
|
Laryngeal cancer is a malignancy arising in the tissues of the larynx (voicebox). People who smoke have a higher risk of developing the disaese. Most laryngeal cancers are of squamous cell histology, these can be categorised as either keratinizing or non-keratinizing. There are a variety of other non-squamous cell laryngeal cancers.
Menu: Cancer of the Larynx
Information for Patients and the Public
Information for Health Professionals / Researchers
Latest Research PublicationsInformation Patients and the Public (10 links)
- Laryngeal Cancer Treatment
National Cancer Institute
PDQ summaries are written and frequently updated by editorial boards of experts Further info. - Cancer of the Larynx
Macmillan Cancer Support
Content is developed by a team of information development nurses and content editors, and reviewed by health professionals. Further info. - Laryngeal (larynx) cancer
NHS Choices
NHS Choices information is quality assured by experts and content is reviewed at least every 2 years. Further info.
Covers symptoms, causes, diagnosis, treatment, recovery and prevention. - Laryngeal and Hypopharyngeal Cancer
Cancer.Net
Content is peer reviewed and Cancer.Net has an Editorial Board of experts and advocates. Content is reviewed annually or as needed. Further info. - What You Need to Know About Cancer of the Larynx
National Cancer Institute
Detailed online booklet. - Laryngeal and Hypopharyngeal Cancer
American Cancer Society
Detailed guide in the form of questions and answers. - Laryngeal cancer statistics
Cancer Research UK
Statistics for the UK, including incidence, mortality, survival, risk factors and stats related to treatment and symptom relief. - Laryngeal Cancer: The Basics
Oncolink - Larynx or laryngeal cancer (cancer of the voice box)
Cancer Research UK - Speech therapy and voice restoration after head and neck cancer
Macmillan Cancer Support
Macmillan Speech and Language Therapist Kelly talks about speech therapy for people who have difficulties with swallowing or speaking due to head and neck cancer. She explains what the larynx (voicebox) is, what surgery for laryngeal cancer involves and how afterwards, breathing and speaking can be done through a stoma in the neck rather than mouth (voice restoration).
Information for Health Professionals / Researchers (8 links)
- PubMed search for publications about Laryngeal Cancer - Limit search to: [Reviews]
PubMed Central search for free-access publications about Laryngeal Cancer
MeSH term: Laryngeal Neoplasms
US National Library of Medicine
PubMed has over 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Constantly updated. - Laryngeal Cancer Treatment
National Cancer Institute
PDQ summaries are written and frequently updated by editorial boards of experts Further info. - Laryngeal Cancer
Patient UK
PatientUK content is peer reviewed. Content is reviewed by a team led by a Clinical Editor to reflect new or updated guidance and publications. Further info. - Glottic Cancer
Medscape
Detailed referenced article by William Lydiatt, MD - Laryngeal cancer
European Cancer Observatoty
Data on incidence, mortality and prevalence by country. - Laryngeal Cancer
Oncolex - Oslo University Hospital (Norway) and MD Andersen (USA)
Detailed reference article covering etiology, histology, staging, metastatic patterns, symptoms, differential diagnoses, prognosis, treatment and follow-up. - Laryngeal cancer statistics
Cancer Research UK
Statistics for the UK, including incidence, mortality, survival, risk factors and stats related to treatment and symptom relief. - SEER Stat Fact Sheets: Larynx
SEER, National Cancer Institute
Detailed population-based statistics for incidence, risk, prevalence, mortality and survival.
Latest Research Publications
This list of publications is regularly updated (Source: PubMed).
Primary solitary extramedullary plasmacytoma involving the true vocal cords in a pregnant woman.
Tumori. 2013 Jan-Feb; 99(1):e14-8 [PubMed]
Salvage transoral laser supraglottic laryngectomy after radiation failure: a report of seven cases.
Ann Otol Rhinol Laryngol. 2013; 122(2):85-90 [PubMed]
METHODS: Between December 1999 and May 2011,7 patients (6 men and 1 woman) underwent transoral laser supraglottic laryngectomy after radiation failure. We conducted 4 different types of endoscopic supraglottic laryngectomy. In the cases with lymph node metastasis, we performed neck dissection at the time of laser surgery.
RESULTS: All patients had recurrent squamous cell carcinoma confirmed on the surgical specimen. Two patients were classified as having T1 disease, 2 as having T2 disease, and 3 as having T3 disease with preepiglottic space involvement. The 2- and 5-year overall survival rates were 85.7% and 68.6%, respectively. There was a recurrence at 8 months of followup after laser surgery in 1 patient; he underwent successful salvage total laryngectomy. The ultimate local control rate was 100%, and the laryngeal preservation rate was 85.7%. The hospitalization times ranged from 2 to 32 days (mean, 15.6 days). The mean decannulation time was 10.7 days (range, 5 to 30 days). All patients started oral feeding within 1 to 3 days after surgery.
CONCLUSIONS: Salvage transoral laser supraglottic laryngectomy following radiation failure seems a feasible and oncologically safe procedure in recurrent supraglottic cancers ranging from T1 to selected T3 with minimal preepiglottic space involvement. It can be an option for minimally invasive organ preservation surgery with lesser morbidity for recurrent supraglottic cancer.
Laryngeal cancer: smoking is not the only risk factor.
B-ENT. 2012; 8(4):273-8 [PubMed]
MATERIALS/METHODS: A case-control study included 70 patients with histologically confirmed laryngeal cancer and 70 controls with non-neoplastic conditions unrelated to diet/smoking/alcohol. Relative risk, odds ratio (OR), and 95% confidence intervals were estimated using multiple logistic regression.
RESULTS: Current smokers had 19.46 OR of laryngeal cancer compared to non-smokers (p = 0.006). The respective OR for alcohol consumption was 3.94 (p = 0.006). While the risk increased in heavy drinkers, there was no difference in duration of alcohol consumption. There was a strong and consistent relation between laryngeal cancer and the consumption of Greek/Turkish coffee cups/day (p = 0.002, OR = 1.77). Diesel exhaust fumes also seemed to increase the risk of laryngeal cancer, although the association was found to be no longer significant after analysis with logistic regression.
CONCLUSION: The present study confirmed the relation of smoking and alcohol with laryngeal cancer. However, other factors such as coffee and diesel exhaust fumes may play an important role in laryngeal carcinogenesis.
Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma.
Strahlenther Onkol. 2013; 189(3):202-14 [PubMed]
PATIENTS AND METHODS: We assessed relative messenger RNA expression of EGFR, Akt1, 2, and 3, mTOR and CCND1, copy number variants of the EGFR and CCND1 genes and immunohistochemical protein expression of EGFR, p-Akt308, p-Akt473, pmTOR, PTEN, p53 and cyclin D1 in paraffin-embedded tissue samples of localized laryngeal carcinomas.
RESULTS: In 289 patients with T3-4 (77.8%), node-negative (84.1%) tumors of the larynx, high EGFR and CCND1 mRNA correlated with no or ex-smoking, (p = 0.003 and p = 0.029, respectively), while low Akt3 mRNA correlated with alcohol abuse, N0 stage, total laryngectomy, and absence of neck dissection. At a median follow-up of 74.5 months, high mTOR mRNA expression was marginally associated with shorter disease-free survival (hazard ratio [HR] = 1.54; p = 0.093) and high Akt3 mRNA with shorter overall survival (HR = 1.49; p = 0.0786), in univariate analysis. In multivariate analysis, node-positive status, subglottic-transglottic location, surgery other than total laryngectomy and mTOR/CCND1 mRNA interaction with a hazard ratio of 2.16 (p value for interaction: 0.0010) were independent predictors of relapse, while node-positive status and subglottic-transglottic location were associated with higher risk for death.
CONCLUSION: In localized laryngeal cancer, clinicopathological parameters and an interaction of high mTOR and CCND1 mRNA expression were found to be associated with poor patient outcome.
Epidemiology and clinical characteristics of larynx and hypopharynx carcinoma: a comparative study in the Hainaut and review of the literature.
Acta Chir Belg. 2012 Nov-Dec; 112(6):423-5 [PubMed]
METHODS: A complete chart review of all patients records was conducted. All the patients who were diagnosed as having laryngeal or hypopharyngeal cancer from January 1, 2004 through December 31, 2009 were included in the study. The demographics of the patient population, the disease profile were analyzed.
RESULTS: 138 patients with laryngeal or hypopharyngeal disease were treated. 76 patients presented a laryngeal cancer. Disease characteristics indicated that most cases of supraglottic cancer were in a locally advanced stage (84.4%), whereas most patients with glottis cancer were diagnosed with early stage (63.3%). A hypopharyngeal cancer was diagnosed in 62 cases. A significant increasing trend in hypopharyngeal cancer has been seen in males. The majority of the patients was alcohol consumers and had a histology showing squamous cell carcinoma. There were 33 females and 105 males whose ages ranged at presentation from 47 to 86 years. Of the 138 patients treated, 24 and 47 patients were respectively T3 and T4 and 37 patients were N1, 37 patients N2 and 10 patients N3 (Table I). Most patients had stage IV disease (65/138). Majority of cases presented with local advanced stage. Of the 138 patients treated, 24 and 47 patients were respectively T3 and T4. The highest rate of local advanced stage was observed in patients with pyriform sinus carcinomas (81%); the lowest rate was observed for glottis tumors (41.8%). Regional lymph node metastases were diagnosed in 61% of the analyzed cases. 37 patients were N1, 37 patients N2 and 10 patients N3. The highest rate (82.2%) of regional lymph node metastases were observed in cases of pyriform sinus carcinomas, and the lowest (31.7%) in glottis carcinomas. Most patients had stage IV disease (65/138). 49 patients received radiotherapy; 48 patients were treated by surgery followed by (chemo)radiotherapy. 41 patients were treated initially by concomitant chemoradiotherapy.
CONCLUSION: A tendency for increasingly younger patients to develop larynx and hypopharynx carcinomas was observed. Most patients had stage IV disease but no trend for a percentage increase in locally advanced tumors was observed. A significant increasing trend in hypopharyngeal cancer has been seen in males.
Larynx preservation: advantages and limitations.
Coll Antropol. 2012; 36 Suppl 2:231-3 [PubMed]
Small cell neuroendocrine tumor of the larynx--a small case series.
Coll Antropol. 2012; 36 Suppl 2:201-4 [PubMed]
Neuroendocrine tumors of larynx--two case reports and literature review.
Coll Antropol. 2012; 36 Suppl 2:173-8 [PubMed]
Relationship of E-cadherin with cervical lymph node metastasis in laryngeal cancer.
Coll Antropol. 2012; 36 Suppl 2:119-24 [PubMed]
Epidemiology of laryngeal cancer in Osijek-Baranja County (eastern Croatia).
Coll Antropol. 2012; 36 Suppl 2:107-10 [PubMed]
Influential factors, complications and survival rate of primary and salvage total laryngectomy for advanced laryngeal cancer.
Coll Antropol. 2012; 36 Suppl 2:7-12 [PubMed]
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
J Clin Oncol. 2013; 31(7):853-9 [PubMed]
PATIENTS AND METHODS: Previously untreated patients with stage III to IV larynx/hypopharynx squamous cell carcinoma received three cycles of ICT-docetaxel and cisplatin 75 mg/m(2) each on day 1 and fluorouracil 750 mg/m(2) per day on days 1 through 5. Poor responders (< 50% response) underwent salvage surgery. Responders (≥ 50% response) were randomly assigned to conventional radiotherapy (RT; 70 Gy) with concurrent cisplatin 100 mg/m(2) per day on days 1, 22, and 43 of RT (arm A) or concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B). Primary end point was LP at 3 months. Secondary end points were larynx function preservation (LFP) and overall survival (OS) at 18 months.
RESULTS: Of the 153 enrolled patients, 116 were randomly assigned after ICT (60, arm A; 56, arm B). Overall toxicity of both CRT and BRT was substantial following ICT. However, treatment compliance was higher in the BRT arm. In an intent-to-treat analysis, there was no significant difference in LP at 3 months between arms A and B (95% and 93%, respectively), LFP (87% and 82%, respectively), and OS at 18 months (92% and 89%, respectively). There were fewer local treatment failures in arm A than in arm B; salvage surgery was feasible in arm B only.
CONCLUSION: There is no evidence that one treatment was superior to the other or could improve the outcome reported with ICT followed by RT alone (French Groupe Oncologie Radiothérapie Tête et Cou [GORTEC] 2000-01 trial [Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma]). The protocol that can best compare with RT alone after ICT is still to be determined.
Larynx preservation for patients with locally advanced laryngeal cancer.
J Clin Oncol. 2013; 31(7):840-4 [PubMed]
Glottic and supraglottic laryngeal cancer: epidemiology, treatment patterns and survival in 164 patients.
J BUON. 2012 Oct-Dec; 17(4):700-5 [PubMed]
METHODS: A series of 164 patients with laryngeal glottic and supraglottic squamous cell cancer (SCC) treated surgically, with radiation therapy (RT), chemotherapy or combination of these was analysed. After treatment, all patients were followed up for an average of 58 months. All data concerning the primary lesion, therapeutic management, recurrence, staging, 5-year overall survival and epidemiological characteristics such as smoking and alcohol abuse were recorded and analysed in combination with the follow up data.
RESULTS: The therapeutic approach most commonly used was RT for stage I tumors and surgery for stages II, III and IV. Stage I and II patients treated with RT had high recurrence rate (60%). Patients with recurrence had 45.3% 5-year overall survival rate and average survival time 80 months, whereas patients with no recurrence had 77.4% 5-year overall survival rate and average survival time 173 months (p=0.0001). There was significant difference in survival between stage I and III (p=0.035), stage I and IV (p=0.0038) and stage II and IV (0.0156). The average overall survival time for non smokers was 195 months (median 1707rpar;, while for smokers it was 99 months (median 100; p=0.0047). The average overall survival time for alcohol abusers was 79 months (median 54), while for those who did not use alcohol it was 153 months (median 150; p=0.016).
CONCLUSION: The 5-year overall survival rate was 61.3%. RT alone in stages I and II proved inferior in decreasing re-currences compared with surgery. Smokers had significantly shorter overall survival.
Dexmedetomidine use in direct laryngoscopic biopsy under TIVA.
Middle East J Anesthesiol. 2012; 21(4):605-12 [PubMed]
METHODS: In this double blind randomised study, patients were allocated to receive dexmedetomidine 0.5 microg/kg (group D, n = 20) or saline placebo (group P, n = 20) intravenously. Forty ASA I-III patients were infused propofol and administered rocuronium bromur. They were intubated and performed biopsy. Aldrete scores, intraoperative propofol and postoperative analgesic requirements, satisfaction scores, recovery time, Ramsay sedation scale (RSS), haemodynamic changes and side effects were recorded.
RESULTS: Postoperative analgesic requirement in group D was significantly lower and satisfaction scores and RSS were significantly higher than in group P. Additionally, MAP (mean arterial blood pressure) significantly decreased at post-extubation time in group D.
CONCLUSION: The premedication with a single dose of dexmedetomidine decreases intraoperative propofol and postoperative analgesic requirements, increases the postoperative satisfaction and RSS considerably in patients undergoing DLB under TIVA.
Chondrosarcoma of the larynx.
Isr Med Assoc J. 2012; 14(11):681-4 [PubMed]
OBJECTIVES: To describe six patients with laryngeal chondrosarcoma from a single center.
METHODS: The medical records of a major tertiary hospital were reviewed for all patients with laryngeal chondrosarcoma diagnosed and treated from 1959 to 2010. Data on background, clinical treatment and outcome were collected.
RESULTS: Six patients, all males with a mean age of 53.3 years, were identified. Partial laryngectomy was performed in three patients, and total laryngectomy, local excision, and partial cricoidectomy in one patient each. Four patients had a permanent tracheostomy after surgery. One patient required postoperative chemotherapy and one radiotherapy. Follow-up time was 12-216 months (mean 102 months). Recurrence developed in two patients 2 and 8 years after initial treatment and was treated by salvage surgery in both patients. One patient died during the follow-up from an unrelated cause. The others are currently alive.
CONCLUSIONS: This study supports earlier reports recommending initial treatment with partial or total laryngectomy for laryngeal chondrosarcoma. Long-term follow-up for recurrence is advised. We recommend preserving the larynx, if possible, even if a permanent tracheostomy is necessary.
Expression of E-cadherin and α-catenin in T1 N0 laryngeal cancer.
Anticancer Res. 2012; 32(12):5245-9 [PubMed]
MATERIALS AND METHODS: Fifty-five T1 N0 laryngeal biopsies were tested by immunohistochemistry for the E-cadherin/α-catenin adhesion complex.
RESULTS: High immunohistochemical expression of E-cadherin and α-catenin was found in 18% and 53% cases, respectively. Expression of both adhesion molecules decreased according to histological grading; a significant relationship was particularly found between high E-cadherin expression and G1 cases (p=0.013). High E-cad-herin expression was statistically associated with in situ carcinoma (p=0.006). Non-statistical significance was evidenced between these adhesion molecules and tobacco use or site of occurence. Regarding clinical outcome, recurrence was associated with low expression of both adhesion molecules.
CONCLUSION: E-cadherin and α-catenin down-regulation might be associated with neoplastic transformation in laryngeal tissues and might be regarded as a risk factor for clinical recurrence.
Tracheal bronchus with metachronous tumor.
J Bronchology Interv Pulmonol. 2012; 19(4):343-4 [PubMed]
Identical human papillomavirus (HPV) genomic variants persist in recurrent respiratory papillomatosis for up to 22 years.
J Infect Dis. 2013; 207(4):583-7 [PubMed]
Pitfalls in the staging of cancer of the laryngeal squamous cell carcinoma.
Neuroimaging Clin N Am. 2013; 23(1):81-105 [PubMed]
The prognostic value of p53, Bcl-2 and Bax expression in laryngeal cancer.
J Med Assoc Thai. 2012; 95(10):1317-20 [PubMed]
MATERIAL AND METHOD: Ninety-four patients diagnosed with laryngeal squamous cell carcinoma were analyzed for 5-year overall survival in relation to immunohistochemical expression of p53, Bcl-2, and Bax proteins.
RESULTS: The present study included 86 males and eight females with a mean age of 65.1 years. Half of the patients (51%) were in stages III and IV. Radiation (44.7%) and radiation plus surgery (40.4%) were the main treatments. The frequency of p53, Bcl-2, and Bax expression was 58.1%, 18.5%, and 87.2%, respectively. The 5-year overall survival rate was 49.7%. Univariate analysis revealed that T-stage, N-stage and treatment were significantly associated with 5-year overall survival. In the multivariate Cox regression, T-stage, treatment, and Bcl-2 expression were significantly associated with survival. Positive Bcl-2 expression was associated with better survival (Hazard ratio 0.23, 95% CI 0.06-0.81).
CONCLUSION: The positive Bcl-2 expression is an independent prognostic marker in laryngeal squamous cell carcinoma.
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
J Clin Oncol. 2013; 31(7):845-52 [PubMed] Article available free on PMC after 01/03/2014
PATIENTS AND METHODS: Patients with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction cisplatin/fluorouracil (PF) followed by RT (control arm), concomitant cisplatin/RT, or RT alone. The composite end point of laryngectomy-free survival (LFS) was the primary end point.
RESULTS: Five hundred twenty patients were analyzed. Median follow-up for surviving patients is 10.8 years. Both chemotherapy regimens significantly improved LFS compared with RT alone (induction chemotherapy v RT alone: hazard ratio [HR], 0.75; 95% CI, 0.59 to 0.95; P = .02; concomitant chemotherapy v RT alone: HR, 0.78; 95% CI, 0.78 to 0.98; P = .03). Overall survival did not differ significantly, although there was a possibility of worse outcome with concomitant relative to induction chemotherapy (HR, 1.25; 95% CI, 0.98 to 1.61; P = .08). Concomitant cisplatin/RT significantly improved the larynx preservation rate over induction PF followed by RT (HR, 0.58; 95% CI, 0.37 to 0.89; P = .0050) and over RT alone (P < .001), whereas induction PF followed by RT was not better than treatment with RT alone (HR, 1.26; 95% CI, 0.88 to 1.82; P = .35). No difference in late effects was detected, but deaths not attributed to larynx cancer or treatment were higher with concomitant chemotherapy (30.8% v 20.8% with induction chemotherapy and 16.9% with RT alone).
CONCLUSION: These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS. Locoregional control and larynx preservation were significantly improved with concomitant cisplatin/RT compared with the induction arm or RT alone. New strategies that improve organ preservation and function with less morbidity are needed.
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.
Virchows Arch. 2013; 462(1):73-81 [PubMed]
Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis.
J Infect Dis. 2013; 207(3):479-88 [PubMed]
METHODS: We systematically reviewed studies on HPV infection and laryngeal cancer published up to 15 May 2012 and quantitatively summarized the prevalence of HPV infection and its association with the risk of laryngeal cancer by means of meta-analysis.
RESULTS: In total, 55 eligible studies were included. The overall HPV prevalence in laryngeal cancer tissues was 28.0% (95% confidence interval [CI], 23.5%-32.9%). A total of 26.6% laryngeal cancer patients were infected with high-risk HPV types only, and HPV-16 was most frequently observed type, with a prevalence of 19.8% (95% CI, 15.7%-24.6%). The meta-analysis based on 12 eligible case-control studies suggests a strong association between HPV infection and laryngeal squamous cell carcinoma, with a summary odds ratio (OR) of 5.39 (95% CI, 3.25-8.94). Different magnitudes of association were observed for HPV-16 (OR, 6.07; 95% CI, 3.44-10.70) and HPV-18 (OR = 4.16; 95% CI, .87-20.04; P < .01). Stratified analyses were performed with respect to HPV genotypes and characteristics of the study population.
CONCLUSIONS: HPV infection, especially infection due to the high-risk type HPV-16, was found to be significantly associated with the risk of laryngeal squamous cell carcinoma.
Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.
Strahlenther Onkol. 2013; 189(1):26-32 [PubMed]
PATIENTS AND METHODS: Nineteen patients with primary squamous cell carcinoma of the subglottis received radiotherapy, 14 of whom also underwent chemotherapy. Of the 19 patients, 15 received definitive radiotherapy to the gross tumors with total doses of 70-70.2 Gy in 35-39 fractions, and 4 underwent preoperative radiotherapy with total doses of 37.8-55.8 Gy in 21-31 fractions, followed by total laryngectomy.
RESULTS: Of the 19 patients, 5 developed local progression and 2 developed distant metastasis at the median follow-up period of 5 years. The 5-year local control and disease-free rates were 74 and 63%, respectively. Three patients died of tumor progression, and the 5-year overall and disease-free survival rates were 80 and 63%, respectively. Regarding acute toxicities, transient mucositis and dermatitis of grade 3 or lower were observed in all patients, but there were no late toxicities of grade 3 or higher.
CONCLUSION: Radiotherapy is a safe and effective treatment for patients with primary squamous cell carcinoma of the subglottis. The use of chemotherapy together with radiotherapy may enhance treatment efficacy and contribute to larynx preservation through good local control.
Modified supracricoid laryngectomy: oncological and functional outcomes in the elderly.
Clin Interv Aging. 2012; 7:475-80 [PubMed] Article available free on PMC after 01/03/2014
METHODS: Clinical records from 21 consecutive patients affected by glottic cancer and treated by modified SCL between 2004 and 2009 were retrospectively reviewed. Postoperative parameters and quality of voice after modified SCL were retrospectively reviewed. Actuarial overall survival, disease-specific survival rates, and recurrence-free survival rates were assessed. The functional and oncological outcomes of patients over 65 years were compared with those of patients younger than 65 years of age.
RESULTS: There were no postoperative complications and all of the patients had complete swallowing rehabilitation. Twenty of the 21 patients had decannulation. Two patients received total laryngectomy for locoregional relapse. Overall survival and disease-specific survival rates were 100%. Recurrence-free survival rates were 90.1% and 90% in patients younger and older than 65 years of age, respectively. The larynx preservation index was lower in patients who were older than 65 years of age. The postoperative courses with regard to functional outcome and voice quality in elderly patients were similar to those of patients younger than 65 years of age.
CONCLUSION: Modified SCL is a new open organ preservation surgical technique that is oncologically safe. The positive functional and oncological outcomes of this surgical procedure allow it to be performed in elderly patients.
Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway.
Tumour Biol. 2012; 33(6):2007-17 [PubMed]
Oncologic and functional outcomes of partial laryngeal surgery for intermediate-stage laryngeal cancer.
Otolaryngol Head Neck Surg. 2013; 148(2):235-42 [PubMed]
STUDY DESIGN: Historical cohort study.
SETTING: Single tertiary care center.
SUBJECTS AND METHODS: Retrospective review of oncologic and functional outcomes in intermediate-stage (T2-3/N0-1, stage II and III) LSCC patients who underwent TLM or SCL from 1998 to 2010.
RESULTS: Sixty patients were included, of whom 28 (47%) underwent TLM and 32 (53%) underwent SCL. For the entire cohort, 2- and 5-year probabilities were 86.2% (95% confidence interval [CI], 73.0%-93.2%) and 72.9% (95% CI, 52.4%-85.6%), respectively, for overall survival (OS) and 79.3% (95% CI, 65.6%-88.0%) and 62.4% (95% CI, 41.9%-77.4%), respectively, for recurrence-free survival (RFS). There was no difference between the TLM and SCL cohorts in OS (P = .542) or RFS (P = .483). More than 75% of patients avoided adjuvant therapy. Communication Scale and Functional Outcome Swallowing Scale scores at median follow-up of 33 months were 2 or better in 97% and 91% of patients, respectively, reflecting functional voice and swallowing postoperatively. Eighty-eight percent of patients retained a functional larynx.
CONCLUSION: PLS provides excellent oncologic and functional outcomes for intermediate-stage LSCC and should be considered an alternative to chemoradiation or total laryngectomy in selected patients.
Managing chondrosarcoma of the epiglottis: a case report.
Ann R Coll Surg Engl. 2012; 94(8):e240-2 [PubMed]
This page last updated: 22nd May 2013
Displaying links verified within last 2 weeks at time of update.
